Pharma Partnerships

For OSE Immunotherapeutics, partnerships and out-licensing deals with global pharmaceutical companies represent ways to rapidly advance the clinical development of its product candidates. Selective partnerships represent a key piece of OSE Immunotherapeutics business model that can contribute significantly to the cash flow needed to continue discovering and developing new targets and therapeutic candidates.

OSE Immunotherapeutics is actively pursuing a partnership strategy with potential pharmaceutical partners.

Existing partnerships signed with premier international pharmaceutical companies for the clinical development of the Company’s most advanced and innovative programs include the following:

• AbbVie (February 2024) : A global licence and collaboration agreement to develop, manufacture and commercialize OSE-230 (renamed ABBV-230) in chronic and severe inflammation.
• Boehringer Ingelheim :
  A global license and collaboration agreement to develop anti-SIRPα BI 765063 (OSE-172) in multiple cancer indications, was signed in April 2018.In May 2024, two new projects were added to the ongoing anti-SIRPα immuno-oncology programs:

  – Reflecting an amendment of the existing collaboration and license   agreement for the anti-SIRPα immuno-oncology compounds BI 765063 and BI 770371, which are being investigated in Phase I clinical studies in advanced solid tumors, development will now also be pursued in cardiovascular-renal-metabolic (CRM) diseases.

  – A new preclinical program will be launched to develop immune-cell activating treatments based on OSE’s cis-targeting anti-PD1/cytokine platform via an asset acquisition.

• Veloxis Pharmaceuticals (April 2021): A global license agreement granting Veloxis worldwide rights to develop, manufacture and commercialize FR104 for all transplant indications (in parallel, OSE Immunotherapeutics retains all product rights to develop FR104 in autoimmune diseases).
• Chong Kun Dang Pharmaceutical Corporation(CKD) (November 2019):  A licensing deal for potential registration and commercialization of Tedopi® in Korea.

Each of these agreements includes an initial upfront payment as well as milestone payments and royalties on potential future sales.

Together, existing partnerships represent a potential of up to €2.1 billion of revenue for OSE Immunotherapeutics and additional royalties on future sales, demonstrating our expertise discovering valuable new targets and therapies and validating the high potential of our drug candidates.